C9orf72 and amyotrophic lateral sclerosis: An ongoing phase 1/2 clinical trial showed that after 3 months of treatment, WVE-004 reduced poly-GP DPRs in cerebrospinal fluid, a key biomarker for C9ORF72-associated ALS patients (Wave Life Sciences Ltd, 2021; Meglio, 2022b).